(0.15%) 5 139.25 points
(0.10%) 38 480 points
(0.23%) 17 888 points
(-0.26%) $83.63
(1.09%) $1.944
(0.30%) $2 354.20
(0.62%) $27.71
(1.69%) $937.65
(-0.16%) $0.933
(-0.29%) $10.99
(-0.27%) $0.798
(1.25%) $93.02
@ $35.38
发出时间: 22 Mar 2024 @ 02:07
回报率: -39.57%
上一信号: Mar 20 - 23:15
上一信号:
回报率: 1.94 %
Live Chart Being Loaded With Signals
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States...
Stats | |
---|---|
今日成交量 | 1.24M |
平均成交量 | 1.53M |
市值 | 1.75B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-1.450 ) 2024-05-08 |
Last Dividend | $0.225 ( 2014-02-04 ) |
Next Dividend | $0 ( N/A ) |
P/E | -12.43 |
ATR14 | $0.0280 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Simon Amy | Sell | 7 157 | Common Stock |
2024-04-02 | Simon Amy | Sell | 16 530 | Common Stock |
2024-04-01 | Bellon Christine | Sell | 3 401 | Common Stock |
2024-04-01 | Burrell Terry-ann | Sell | 5 446 | Common Stock |
2024-04-01 | Evans John M. | Sell | 18 102 | Common Stock |
INSIDER POWER |
---|
-13.27 |
Last 98 transactions |
Buy: 1 500 214 | Sell: 1 914 982 |
音量 相关性
Beam Therapeutics Inc 相关性 - 货币/商品
Beam Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $377.71M |
毛利润: | $357.70M (94.70 %) |
EPS: | $-1.720 |
FY | 2023 |
营收: | $377.71M |
毛利润: | $357.70M (94.70 %) |
EPS: | $-1.720 |
FY | 2022 |
营收: | $60.92M |
毛利润: | $38.34M (62.94 %) |
EPS: | $-3.76 |
FY | 2021 |
营收: | $51.84M |
毛利润: | $51.84M (100.00 %) |
EPS: | $-5.77 |
Financial Reports:
No articles found.
Beam Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.190 | 2011-11-07 |
Last Dividend | $0.225 | 2014-02-04 |
Next Dividend | $0 | N/A |
Payout Date | 2014-03-03 | |
Next Payout Date | N/A | |
# dividends | 10 | -- |
Total Paid Out | $2.16 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.6 | -- |
Div. Sustainability Score | 1.443 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.318 | 1.500 | -6.36 | -9.54 | [0 - 0.5] |
returnOnAssetsTTM | -0.0823 | 1.200 | -2.74 | -3.29 | [0 - 0.3] |
returnOnEquityTTM | -0.144 | 1.500 | -2.71 | -4.07 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.89 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.79 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.12 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.119 | -1.500 | 8.02 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -5.10 | 1.000 | -3.00 | -3.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.845 | 2.00 | -0.615 | -1.230 | [0 - 30] |
freeCashFlowPerShareTTM | -2.26 | 2.00 | -1.131 | -2.26 | [0 - 20] |
debtEquityRatioTTM | 0.176 | -1.500 | 9.29 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.928 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.467 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.862 | 1.000 | -5.90 | -5.90 | [0.2 - 2] |
assetTurnoverTTM | 0.259 | 0.800 | -1.608 | -1.287 | [0.5 - 2] |
Total Score | 1.443 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -14.39 | 1.000 | -1.555 | 0 | [1 - 100] |
returnOnEquityTTM | -0.144 | 2.50 | -1.744 | -4.07 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.26 | 2.00 | -0.754 | -2.26 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.845 | 2.00 | -0.615 | -1.230 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.395 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.37 |
Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。